STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANGO
  4. [Form 4] ANGIODYNAMICS INC Insider Trading Activity

AngioDynamics (NASDAQ: ANGO) executive settles 20,052 performance units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Warren Nighan Jr., SVP Quality and Regulatory at AngioDynamics, had a 2023 performance share unit grant settle. A target award of 20,052 performance share units led to the issuance of 5,694 shares of common stock based on performance, with the remaining units forfeited. Of the shares issued, 1,671 were withheld at $13.82 per share to satisfy tax withholding obligations.

Positive

  • None.

Negative

  • None.
Insider Nighan Warren JR
Role SVP Quality and Regulatory
Type Security Shares Price Value
Exercise Performance Right F3 20,052 $0.00 $0.00
Exercise Common Stock F1 5,694 $0.00 $0.00
Tax Withholding Common Stock F2 1,671 $13.82 $23K
Holdings After Transaction: Performance Right — 0 shares (Direct); Common Stock — 88,115 shares (Direct)
Footnotes (3)
  1. F1. This acquisition of 5,694 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
  2. F2. The exempt disposition of 1,671 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
  3. F3. On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
Performance share units granted 20,052 units Target grant received on July 19, 2023
Shares issued from PSUs 5,694 shares Common stock issued upon vesting and settlement of 2023 performance share units
Shares withheld for taxes 1,671 shares Common stock withheld to satisfy tax withholding obligations on vesting
Tax withholding price $13.82 per share Price used to value shares withheld for tax obligations
Performance measurement period 2024, 2025, 2026 Fiscal years used to determine performance for the 2023 performance share unit grant
Earnout range 0% to 200% of target Range of performance share units that could be earned based on performance metrics
TSR-based adjustment 20% Portion of earned shares subject to adjustment based on relative total shareholder return
performance share units financial
"the reporting person received a target grant of 20,052 performance share units"
Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.
tax withholding obligations financial
"disposition of 1,671 shares of Common Stock was made to satisfy tax withholding obligations"
total shareholder return financial
"based on total shareholder return relative to a peer group of companies"
Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.
peer group of companies financial
"total shareholder return relative to a peer group of companies over a three-year"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider activity did AngioDynamics (ANGO) report for Warren Nighan Jr.?
Warren Nighan Jr. reported settlement of a 2023 performance share unit grant. The award produced 5,694 common shares, while the rest of the 20,052 target units were forfeited, and some shares were withheld to cover taxes.

How many AngioDynamics (ANGO) shares did the executive receive from performance units?
The executive received 5,694 shares of common stock from a 2023 grant of performance share units. These shares were issued after the compensation committee evaluated multi-year performance metrics for fiscal years 2024, 2025 and 2026.

How many AngioDynamics (ANGO) shares were originally granted as performance share units?
The 2023 award gave the executive a target grant of 20,052 performance share units. Between 0% and 200% of this target could be earned, with a further 20% adjustment tied to relative total shareholder return over three fiscal years.

Why were some AngioDynamics (ANGO) shares disposed of in this Form 4?
The Form 4 shows an exempt disposition of 1,671 shares of common stock. These shares were withheld at $13.82 per share solely to satisfy tax withholding obligations arising from the vesting of the performance share units.

Were any AngioDynamics (ANGO) performance share units forfeited in this transaction?
Yes. From the 20,052 target performance share units granted in 2023, only 5,694 shares of common stock were ultimately issued based on performance, and the remaining units under that grant were forfeited.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nighan Warren JR
(Last)(First)(Middle)
ANGIODYNAMICS, INC.
14 PLAZA DRIVE
(Street)
LATHAM NEW YORK 12110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP Quality and Regulatory
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/22/2026M5,694(1)A$089,786D
Common Stock07/22/2026F1,671(2)D$13.8288,115D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Right(3)07/22/2026M20,052 (3) (3)Common Stock20,052$00D
Explanation of Responses:
1. This acquisition of 5,694 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
2. The exempt disposition of 1,671 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
3. On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
/s/ Lawrence T. Weiss, Attorney in Fact07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR